BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

...won bids for seven products: irbesartan, irbesartan/hydrochlorothiazide, lisinopril, losartan, and fosinopril for cardiovascular disorders and risperidone...
BioCentury | Mar 29, 2019
Company News

Luye submits NDA for schizophrenia, bipolar disorder therapy

...next year. Johnson & Johnson (NYSE:JNJ) already markets a long-acting injectable formulation of risperidone as Risperdal Consta...
...three weeks of treatment with Risperdal Consta to maintain therapeutic levels until the main release of risperidone...
...does not require continuation of oral antipsychotic therapy when beginning treatment. Hongjiang Li, Staff Writer LY03004 Risperdal Consta, risperidone (Risperdal depot) Johnson...
BioCentury | Oct 26, 2018
Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

...Negative Syndrome Scale (PANSS) total score from baseline to week 10 vs. continued treatment with risperidone...
BioCentury | Oct 25, 2018
Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

...Negative Syndrome Scale (PANSS) total score from baseline to week 10 vs. continued treatment with risperidone...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...treatment Durect Corp. (NASDAQ:DRRX) / Indivior plc (LSE:INDV) FDA approves once-monthly, subcutaneous, long-acting injectable Perseris risperidone...
BioCentury | Aug 3, 2018
Clinical News

FDA approves once-monthly schizophrenia drug from Durect, Indivior

...Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia...
...from Indivior. The companies said Perseris is the first once-monthly, subcutaneous, long-acting injectable (LAI) containing risperidone...
...Cupertino, Calif. Indivior plc (LSE:INDV), Richmond, Va. Product: Perseris risperidone (RBP-7000) Business: Neurology Allison Johnson Perseris (RBP-7000, risperidone) Durect...
BioCentury | Jul 30, 2018
Company News

FDA approves once-monthly schizophrenia drug from Durect, Indivior

...Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia...
...from Indivior. The companies said Perseris is the first once-monthly, subcutaneous, long-acting injectable (LAI) containing risperidone...
...Indivior slipped 4.10p to 310.90p on Monday. Durect was up $0.14 (10%) to $1.55. Allison Johnson RBP-7000, risperidone Durect...
BioCentury | May 11, 2018
Finance

Seroquel stepping stone

...its planned 2H19 launch of its internal schizophrenia and bipolar disorder candidate LY03004, which comprises risperidone...
BioCentury | May 11, 2018
Company News

Luye acquires AstraZeneca antipsychoitic for $538M

...both compounds' approval in China, the U.S., Europe and Japan. LY03004 is a formulation of risperidone...
BioCentury | May 7, 2018
Company News

Luye paying AZ $538M for antipsychotic

...both compounds' approval in China, the U.S., Europe and Japan. LY03004 is a formulation of risperidone...
Items per page:
1 - 10 of 356